Deslanoside

CHEMBL1614 Phase 4 Zugelassen Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
943.1 g/mol
LogP
-0.3
Phase
4

A cardiac glycoside derived from digitalis used to treat heart failure and certain abnormal heart rhythms. It works by strengthening heart muscle contractions and slowing the heart rate.

Molekularmasse

943,1000 g/mol

LogP

-0,30

TPSA

282,00 Ų

Lipinski-Regel der Fünf

Nicht bestanden

Wirkmechanismus

Inhibits the sodium-potassium ATPase pump in cardiac myocytes, increasing intracellular sodium and subsequently calcium via the sodium-calcium exchanger. This enhances cardiac contractility (positive inotropic effect).

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanismus

Inhibits the sodium-potassium ATPase pump in cardiac myocytes, increasing intracellular sodium and subsequently calcium via the sodium-calcium exchanger. This enhances cardiac contractility (positive inotropic effect).

2D-Struktur

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

C[C@H]1O[C@@H](O[C@H]2CC[C@@]3(C)[C@H](CC[C@@H]4[C@@H]3C[C@@H](O)[C@]3(C)[C@@H](C5=CC(=O)OC5)CC[C@]43O)C2)C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1

InChI

InChI=1S/C47H74O19/c1-20-41(64-36-16-30(50)42(21(2)60-36)65-37-17-31(51)43(22(3)61-37)66-44-40(56)39(55)38(54)32(18-48)63-44)29(49)15-35(59-20)62-25-8-10-45(4)24(13-25)6-7-27-28(45)14-33(52)46(5)26(9-11-47(27,46)57)23-12-34(53)58-19-23/h12,20-22,24-33,35-44,48-52,54-57H,6-11,13-19H2,1-5H3/t20-,21-,22-,24-,25+,26-,27-,28+,29+,30+,31+,32-,33-,35+,36+,37+,38-,39+,40-,41-,42-,43-,44+,45+,46+,47+/m1/s1

Molecular Formula

C47H74O19

HBD / HBA

9 / 19

Rotierbare Bindungen

10

Schwere Atome

66

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

A cardiac glycoside derived from digitalis used to treat heart failure and certain abnormal heart rhythms. It works by strengthening heart muscle contractions and slowing the heart rate.

Inhibits the sodium-potassium ATPase pump in cardiac myocytes, increasing intracellular sodium and subsequently calcium via the sodium-calcium exchanger. This enhances cardiac contractility (positive inotropic effect).

Yes, Deslanoside is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1614. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 28620. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.